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Abstract Radiation-induced midbrain ﬁbrosarcoma is a
rare, highly aggressive tumor, which is associated with
poor prognosis. We present the case of a 48-year old man
with brainstem ﬁbrosarcoma 20 years following radiation
therapy received for a pituitary tumor. We discuss this case
in the context of the diagnostic criteria for these tumors,
and previous reports of secondary and primary sarcomas of
the central nervous system.
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Introduction
Secondary ﬁbrosarcoma of the brain is an exceedingly rare
tumor, occurring almost exclusively as a complication of
therapeutic radiation to a preexisting intracranial tumor
[1–5]. Fibrosarcomas are aggressive tumors, with poor
prognosis [6–8]. These tumors tend to spread rapidly with
extensive involvement of the optic nerves, hypothalamus,
and the brain stem, which makes total surgical resection
impossible. No clinical trial for brain ﬁbrosarcoma has
been conducted to date, and current treatment options
based on case reports encompass subtotal resection
attempts [1], Glia-Site brachytherapy system [9], or che-
motherapy [2].
We report a case of a 48 year old man who presented
with a brainstem lesion 20 years after he received radiation
therapy for a pituitary tumor. Upon further investigation,
the new tumor was diagnosed as ﬁbrosarcoma secondary to
radiation therapy. A subtotal resection of the tumor was
performed followed by chemotherapy. We chose to treat
the patient with cyclophosphamide and Gleevec chemo-
therapy and to follow him with serial imaging, which
showed evidence of tumor stability for 6 months.
Case report
Clinical course
A 48-year old Caucasian man presented to clinic for
evaluation of his options for the treatment of brainstem
ﬁbrosarcoma. In 1977, 26 years prior to this presentation,
the patient was diagnosed with a large pituitary adenoma
based on a head computer tomography. Biopsy was not
performed at the time. However, he received conformal
fractionated radiotherapy of unknown dose. He also
had concurrent hydrocephalus and a ventriculo–peritoneal
shunt was placed. The patient was asymptomatic until 2003
when he started to develop eye left eyelid drooping and
diplopia. A magnetic resonance study performed in Feb-
ruary of 2004 showed a right brainstem lesion. Stereotactic
needle brain biopsy was performed but the results were
inconclusive. The patient was followed with serial neuro-
imaging until August of 2006 when the tumor experienced
signiﬁcant growth associated with progressive neurologic
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performed, which also failed to show the pathology of the
tumor. In May of 2007, the patient underwent subtotal
resection of his large right pontine enhancing mass.
Pathology results revealed that the tissue was most con-
sisted with grade 2 ﬁbrosarcoma. Post operatively the
patient suffered a pseudomeningocele at the incision site,
which required a VP shunt revision. Subsequently he pre-
sented to our clinic for reevaluation of this therapeutic
options. After careful consideration of the different options
available we decided to use a combination of metronomic
cyclophosphamide at 50 mg a day and Imatinib 400 mg a
day. The choice of Imatinib was based on the newest
published data on the soft-tissue sarcoma and gastrointes-
tinal stromal tumors sensitivity to Imatinib [10] and the
recent clinical trials showing that this chemotherapy agent
is a potential option for primary malignant gliomas [11].
Cyclophosphamide is very commonly used in the treatment
of multiple CNS malignancies such as malignant glioma
and meningioma [12], and also shows good activity in the
treatment of systemic ﬁbrosarcoma [13] which motivates
our decision to include this drug in this patient’s regimen.
The patient tolerated the treatment well, with slow
improvement in his neurologic function and with minimal
(grade II) chemotherapy-related hematologic toxicities. No
treatment discontinuation was needed. Serial magnetic res-
onance studies of the brain showed that the tumor did not
growoverthecourseof6 monthofchemotherapy,measures
being stable at 30.2 mm 9 35 mm (November 2007) and
30.4 mm 9 35 mm (May 2008) (Fig. 1c–f). Unfortunately,
the patient expired due to bacterial pneumonia with sub-
sequent Gram negative sepsis while continuing to experi-
ence neurologic improvement, 6 months after the onset of
chemotherapy. At the wish of the family, no autopsy was
performed.
Neuropathological examination
The pathology report indicated that the subtotal resection
specimenwasmostconsistentwithbrainstemtissue(Fig. 2c,
d). Microscopical analysis if the specimen revealed spindle
cell proliferation, with mild to moderate pleomorphism
(Fig. 2a,b).ThesecellswerealsonegativeforEMA,GFAP,
Keratin, Melan-A and S 100 (Fig. 2d). In some areas, ten to
ﬁfteen percent of these cells reacted with Ki-67 (Fig. 2h).
These areas were also positive for Vimentin (Fig. 2f) and
showed a delicate reticulin network (Fig. 2e). Faint to
moderatepositivityforp53wasdemonstratedinsomeareas.
A desmin stain was also positive. Within the brain tissue
there were some areas of necrosis in which macrophages
could be seen.
Imaging examination
T1 weighted axial and sagittal images delineated a gado-
linium enhancing midbrain mass with lesional edema. T2
Fig. 1 Axial and coronal MRI
T1 images with contrast.
a, b May 2007 showing tumor
in the midbrain region.
c, d November 2007 showing
tumor progression.
e, f May 2008 showing tumor
stability following
chemotherapy
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123weighted axial images demonstrated a heterogenous
hyperintensity corresponding to the gadolinium-enhancing
areas (Fig. 1). Compared o the MRI from May 2007 the
MRI from November 2007 showed rapidly expanding
tumor (Fig. 1). The follow-up MRIs obtained at 6 months
showed stability of the tumor over a period of 6 month
(Fig. 1).
Discussion
Sarcomas of the central nervous system are exceedingly
rare tumors, accounting for only 1.5% of the total intra-
cranial tumors [14, 15]. They can be classiﬁed in four
categories. First category includes primary brain sarcomas
arising from the mesenchymal tissues. Second category
Fig. 2 Pathology slides
ﬁbrosarcoma: a Spindled
pleomorphic cells of
ﬁbrosarcoma, mitosis in upper
left corner. b Mitotic ﬁgure and
spindle pleomorphic cells of
ﬁbrosarcoma. c H&E stains of
individual malignant cells
inﬁltrating pons. d S-100
immunohistochemical stain,
negative. e Reticulin stain
showing delicate reticulin ﬁbers
between malignant cells.
f Vimentin
immunohistochemical stain,
strongly positive. g GFAP
immunohistochemical stain,
negative. h Ki-67
immunohistochemical stain,
positive, indicating proliferative
activity
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123encompasses sarcomatous transformation of a preexisting
brain tumor, such as meningioma or glioma. Third category
includes radiation induced sarcomas and fourth category is
composed of systemic metastatic sarcomas to the central
nervous system [1–4, 6–8, 15–17]. Post irradiation ﬁbro-
sarcoma of the central nervous system is characterized by
quick and extensive local invasion of the tissues [1, 3].
Literature indicates that these tumors are associated with
rapid clinical decline [1, 2, 8].
In our patient, the histopathologic diagnosis of sarcoma
was based on the hematoxylin and eosin sections which
showed a highly malignant tumor with sheets of spindle
shaped cells, and oval-shaped nuclei with atypia and
pleomorphism. The positive Vimentin stain also supported
the diagnosis of sarcoma, since Vimentin is the major
subunit protein in the intermediate ﬁlaments of mesen-
chymal cells. The delicate reticulin pattern surrounding the
tumor cells with extensive areas of collagen deposition as
well as the positive desmin stain was also consistent with
the diagnosis of ﬁbrosarcoma (Fig. 2).
Similar tootherliterature reports,there wasno histogenic
relationship of the sarcoma to the pituitary adenoma:
immunostaining failed to show evidence of endocrine
functionintheﬁbrosarcomaspecimen.Atthesametime,the
GFAP stain was negative indicating that the tumor was not a
gliosarcoma. This ﬁbrosarcoma most likely appeared from
the adjacent mesenchymal tissues in the sella turcica, dura,
the optic sheath and the basal meninges which received
radiation therapy along with the original pituitary tumor.
Literature reports indicate that ﬁbrosarcoma can convert to
glioblastoma in the setting of continued radiation received
by brain parenchyma [18]. This malignant transformation of
the primary mesenchymal tumor may be due to the effect
radiation has on the adjacent glial tissues and reactive
astrocytes, as well as on the pluripotent mesenchymal cells
in the tumor bed to undergo further malignant transforma-
tion [18]. This process is certainly possible in our patient,
although the GFAP stain indicated that the tumor did not
have a glial component. Since no autopsy was performed to
analyze the entire tumor mass, it is uncertain if areas of the
tumor underwent transformation to gliosarcoma.
Radiation-induced ﬁbrosarcoma has become more com-
monintherecentyearsasthenumberoflong-termsurvivors
consistently increased with new methods of treatment. We
Table 1 Literature review of post irradiation ﬁbrosarcoma cases
Study Age Sex Total radiation
to tumor
Latent
period
Duration of tumor
after radiation (months)
Terry et al. [23] Case 1 47 F 7,500 6.5 3
Terry et al. [23] Case 2 44 M 6,400 2.5 8.5
Terry et al. [23] Case 3 26 F 6,500 12 2
Newton et al. [24] 28 F 3,910 10 6
Goldberg et al. [25] Case 1 28 F 3,940 10.5 1
Goldberg et al. [25] Case 2 31 F 6,000 20 1
Greenhouse [26] 24 F 8,000 7.3 1 1/3
Waltz and Brownell [27] Case 1 38 M 3,500 8 1
Waltz and Brownell [27] Case 2 42 M 4,000 5 6
Ahmad and Fayos [28] 46 M 4,092 10 Unknown
Powell et al. [29] 52 M 5,000 13 6
Pieterse et al. [30] 48 M 4,500 18 12
Shi et al. [1] 54 M 5,000 8 5
Chang and Pool [31] Unknown Unknown Unknown 27 Unknown
Wright [32] Unknown Unknown Unknown 15 Unknown
Amine and Sugar [33] 16 Unknown 5,100 10 Unknown
Gerlach and Janisch [34] 26 Unknown 6,000 20 Unknown
Coppeto and Roberts [35] 46 Unknown 10,000 7 Unknown
Shin et al. [36] 33 Unknown 5,000 11 Unknown
Vikhert and Kasumova [37] Case 1 43 Unknown 10,100 12 Unknown
Vikhert and Kasumova [37] Case 2 58 Unknown 12,000 13 Unknown
Vikhert and Kasumova [37] Case 3 50 Unknown Unknown 8 Unknown
Pages and Broquerie [38] 23 Unknown 5,400 27 Unknown
Nagatani et al. [39] 55 Unknown 5,000 2 Unknown
Martin et al. [40] 18 Unknown 4,500 5 Unknown
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123have identiﬁed 25 cases in the literature (Table 1), where
patients received radiation therapy for a pituitary adenoma.
Subsequently these patients developed ﬁbrosarcomas with a
latent period of 2.5–20 years, with most of the patients
developingthesecondarytumorapproximately10–12 years
after receiving radiation therapy for the initial tumor. From
analyzing these cases, we also inferred a clinical picture of
ﬁbrosarcoma as a highly aggressive tumor, with extensive
inﬁltration in the surrounding tissue and quick progression.
The surgical treatment for these tumors is highly lim-
ited—the areas the tumor extends into are not easily
accessible by traditional or modern neurosurgical tech-
niques, and the resection is limited due to the highly elo-
quent areas the tumor invades. Chemotherapy or additional
radiation are the best options for treating these highly
malignant tumors affecting the brain [19–21].
Presently no clinical trials have been conducted to deﬁne
the optimal chemotherapy regimen appropriate to treat
these tumors. We were able to identify in our extensive
literature search only four case reports which have used
chemotherapy for the treatment of secondary ﬁbrosarcomas
of the brain (see Table 2). The overall survival of the adult
patients described in the case reports were similar to the
one described by us [22]. However, none of the older
chemotherapy regimens contained pathway-selective
drugs. The drugs used had the potential for severe side-
effects and impact on the patient quality of life [2, 9, 14].
With recent advances in molecularly targeted treatments
for cancers, new agents are emerging to treat different
types of sarcomas. Imatinib is one molecule which is
gaining acceptance in the treatment of other types of
ﬁbrosarcoma, such as dermatoﬁbrosarcoma and soft-tissue
sarcomas. Cyclophosphamide is another agent that is
valuable in the treatment of brain neoplasms and has been
used to treat sarcomas with some success. As the two
chemotherapy agents have different targets in the neo-
plastic cells, their combination has a potential synergistic
activity. In our case, this regimen was also very well tol-
erated, with no limiting toxicities.
Conclusions
Post radiation ﬁbrosarcomas most likely arise from the
adjacent tissues which have been exposed to radiation in
the process of treating the primary tumor. The treatment of
these tumors is not well deﬁned, and this severely impacts
their prognosis. New research on the molecular pathology
of radiation-induced brain ﬁbrosarcoma and more targeted
therapies is currently needed. Aggressive therapeutic
approaches are required to maintain tumor control. We
found metronomic cyclophosphamide and Imatinib to be
appropriate therapeutic options for maintaining local tumor
control in a patient with a very aggressive tumor. Our
treatment regimen provided progression free survival for
6 months.
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